Results 81 to 90 of about 545,624 (314)

METTL14 Inhibits Hepatocellular Carcinoma Metastasis Through Regulating EGFR/PI3K/AKT Signaling Pathway in an m6A-Dependent Manner

open access: yesCancer Management and Research, 2020
Yuntao Shi,1,* Yingying Zhuang,2,* Jialing Zhang,1 Mengxue Chen,1 Shangnong Wu1 1Department of Gastroenterology, The Affiliated Huai’an No. 1 People’s Hospital of Nanjing Medical University, Huai’an, People’s Republic of China ...
Shi Y, Zhuang Y, Zhang J, Chen M, Wu S
doaj  

CDK7 Inhibition is Effective in all the Subtypes of Breast Cancer: Determinants of Response and Synergy with EGFR Inhibition

open access: yesCells, 2020
CDK7, a transcriptional cyclin-dependent kinase, is emerging as a novel cancer target. Triple-negative breast cancers (TNBC) but not estrogen receptor-positive (ER+) breast cancers have been reported to be uniquely sensitive to the CDK7 inhibitor THZ1 ...
Martina S.J. McDermott   +6 more
doaj   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

open access: yesMolecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce   +11 more
wiley   +1 more source

EGFR-Mutant Adenocarcinomas That Transform to Small-Cell Lung Cancer and Other Neuroendocrine Carcinomas: Clinical Outcomes.

open access: yesJournal of Clinical Oncology, 2019
PURPOSE Approximately 3% to 10% of EGFR (epidermal growth factor receptor) -mutant non-small cell lung cancers (NSCLCs) undergo transformation to small-cell lung cancer (SCLC), but their clinical course is poorly characterized.
N. Marcoux   +20 more
semanticscholar   +1 more source

Tumour–host interactions in Drosophila: mechanisms in the tumour micro‐ and macroenvironment

open access: yesMolecular Oncology, EarlyView.
This review examines how tumour–host crosstalk takes place at multiple levels of biological organisation, from local cell competition and immune crosstalk to organism‐wide metabolic and physiological collapse. Here, we integrate findings from Drosophila melanogaster studies that reveal conserved mechanisms through which tumours hijack host systems to ...
José Teles‐Reis, Tor Erik Rusten
wiley   +1 more source

The EGFR Polymorphism Increased the Risk of Hepatocellular Carcinoma Through the miR-3196-Dependent Approach in Chinese Han Population [Corrigendum]

open access: yesPharmacogenomics and Personalized Medicine, 2021
Zhang L, Li X, Lu J, et al. Pharmgenomics Pers Med. 2021;14:469–476. Page 470, Materials and Methods, Clinical Samples, second sentence, the text “All blood samples are taken from Liyang People’s Hospital during March 2009 to August ...
Zhang L   +6 more
doaj  

Activation of different growth factor systems in tissues of adenocarcinoma and signet-ring cell carcinoma of the stomach

open access: yesИсследования и практика в медицине, 2019
Purpose of the study. The purpose of the study was to find the difference between local levels of VEGF, EGF, IGFI and IG- FII in tumor and intact tissues in adenocarcinoma of the stomach (AC) and signet-ring cell carcinoma of the stomach (SRCC).Materials
O. I. Kit   +10 more
doaj   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

open access: yesMolecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary   +1 more
wiley   +1 more source

Early‐Phase Research in Pediatric Neuro‐Oncology

open access: yes
Pediatric Blood &Cancer, EarlyView.
Jonathan Cunningham
wiley   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Home - About - Disclaimer - Privacy